

# Mometasone Dry Powder Inhaler Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 437335-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.01.2016

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1 Product identifier

Trade name : Mometasone Dry Powder Inhaler Formulation

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33nd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

### 1.4 Emergency telephone number

+1-215-631-6999

## SECTION 2: Hazards identification

### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B	H360Df: May damage the unborn child. Suspected of damaging fertility.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

### 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :  

Signal word : Danger

Hazard statements : H360Df May damage the unborn child. Suspected of damaging fertility.

## Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

H373 May cause damage to organs through prolonged or repeated exposure.  
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements :

**Prevention:**

P201 Obtain special instructions before use.  
P260 Do not breathe dust.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P391 Collect spillage.

Hazardous components which must be listed on the label:

Mometasone

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410  M-Factor (Chronic aquatic toxicity): 100	>= 10 - < 20

For explanation of abbreviations see section 16.

**Mometasone Dry Powder Inhaler Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

---

**SECTION 4: First aid measures****4.1 Description of first aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

**4.2 Most important symptoms and effects, both acute and delayed**

- Risks : May damage the unborn child. Suspected of damaging fertility.  
May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

**4.3 Indication of any immediate medical attention and special treatment needed**

- Treatment : Treat symptomatically and supportively.
- 

**SECTION 5: Firefighting measures****5.1 Extinguishing media**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing : None known.
-

# Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

---

media

## 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Chlorine compounds

## 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**Mometasone Dry Powder Inhaler Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

---

**6.4 Reference to other sections**

See sections: 7, 8, 11, 12 and 13.

---

**SECTION 7: Handling and storage****7.1 Precautions for safe handling**

- |                         |   |   |
|-------------------------|---|---|
| Technical measures      | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.  |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.   |
| Advice on safe handling | : | Do not get on skin or clothing.<br>Do not breathe dust.<br>Do not swallow.<br>Avoid contact with eyes.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.  |

**7.2 Conditions for safe storage, including any incompatibilities**

- |   |   |  |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.                      |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents<br>Self-reactive substances and mixtures<br>Organic peroxides<br>Explosives<br>Gases |

**7.3 Specific end use(s)**

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

## Mometasone Dry Powder Inhaler Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 437335-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.01.2016

**SECTION 8: Exposure controls/personal protection****8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Mometasone	83919-23-7	TWA	1 µg/m <sup>3</sup> (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

**8.2 Exposure controls****Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

**Personal protective equipment**

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type (P)

**SECTION 9: Physical and chemical properties****9.1 Information on basic physical and chemical properties**

Appearance	:	powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available

# SAFETY DATA SHEET



## Mometasone Dry Powder Inhaler Formulation



Version 3.1      Revision Date: 30.09.2023      SDS Number: 437335-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.01.2016

---

pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Flammability (liquids)	:	No data available
Molecular weight	:	No data available
Particle size	:	No data available

## Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

---

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

**10.4 Conditions to avoid**

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

**10.5 Incompatible materials**

Materials to avoid : Oxidizing agents

**10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

---

**SECTION 11: Toxicological information****11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Mometasone:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
LD50 (Mouse): > 2.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3,3 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3,2 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg  
Application Route: Subcutaneous  
Symptoms: Breathing difficulties



## Mometasone Dry Powder Inhaler Formulation

Version            Revision Date:            SDS Number:            Date of last issue: 04.04.2023  
3.1                30.09.2023                437335-00019            Date of first issue: 28.01.2016

---

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Mometasone:**

Species                                : Rabbit  
Result                                 : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Mometasone:**

Species                                : Rabbit  
Result                                 : No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Mometasone:**

Test Type                                : Maximisation Test  
Exposure routes                        : Dermal  
Species                                 : Guinea pig  
Assessment                               : Does not cause skin sensitisation.  
Result                                    : negative  
Remarks                                 : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Mometasone:**

Genotoxicity in vitro                 : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: positive

## Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

---

	Test Type: Mouse Lymphoma Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
	Test Type: Chromosomal aberration Species: Rat Cell type: Bone marrow Result: negative
	Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Result: negative
Germ cell mutagenicity- Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Components:****Mometasone:**

Species	: Rat
Application Route	: Inhalation
Exposure time	: 2 Years
Dose	: 0.067 mg/kg body weight
Result	: negative

Species	: Mouse
Application Route	: Inhalation
Exposure time	: 19 Months
Dose	: 0.160 mg/kg body weight
Result	: negative

**Reproductive toxicity**

May damage the unborn child. Suspected of damaging fertility.

**Components:****Mometasone:**

Effects on fertility	: Test Type: Fertility Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0,015 mg/kg body weight Symptoms: Reduced embryonic survival, Reduced foetal weight Result: No effects on fertility, Effect on reproduction capacity
----------------------	---

## Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

---

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Subcutaneous  
Embryo-foetal toxicity: LOAEL: 0,06 mg/kg body weight  
Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Dermal  
Embryo-foetal toxicity: LOAEL: 0,3 mg/kg body weight  
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Dermal  
Embryo-foetal toxicity: LOAEL: 0,15 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Subcutaneous  
Embryo-foetal toxicity: LOAEL: 0,15 mg/kg body weight  
Result: Effects on newborn

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 0,7 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**Components:****Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

**STOT - repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

**Components:****Mometasone:**

Exposure routes : inhalation (dust/mist/fume)  
Target Organs : Immune system, Liver, Kidney, Skin  
Assessment : May cause damage to organs through prolonged or repeated exposure.

## Mometasone Dry Powder Inhaler Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 437335-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.01.2016

---

**Repeated dose toxicity****Components:****Mometasone:**

Species : Rat  
NOAEL : 0,005 mg/kg  
LOAEL : 0,3 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog  
LOAEL : 0,5 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat  
NOAEL : 0,00013 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 90 d  
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog  
NOAEL : 0,0005 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 90 d  
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

**Aspiration toxicity**

Not classified based on available information.

**Components:****Mometasone:**

Not applicable

**Experience with human exposure****Components:****Mometasone:**

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion  
Skin contact : Symptoms: Dermatitis, Itching

**Further information****Components:****Mometasone:**

## Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

Remarks : Dermal absorption possible

---

**SECTION 12: Ecological information**
**12.1 Toxicity****Components:****Mometasone:**

Toxicity to fish	:	LC50 (Menidia beryllina (Silverside)): 0,11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility  LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility  EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 3,2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	:	EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility  NOEC : 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC: 0,00014 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 0,34 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

## Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

---

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 100

**12.2 Persistence and degradability****Components:****Mometasone:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 % (12 d)  
Method: OECD Test Guideline 111

**12.3 Bioaccumulative potential****Components:****Mometasone:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 107,1  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4,68

**12.4 Mobility in soil****Components:****Mometasone:**

Distribution among environmental compartments : log Koc: 4,02

**12.5 Results of PBT and vPvB assessment****Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

**12.6 Other adverse effects****Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

---

**SECTION 13: Disposal considerations****13.1 Waste treatment methods**

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

**SECTION 14: Transport information****14.1 UN number**

ADN	:	UN 3077
ADR	:	UN 3077
RID	:	UN 3077
IMDG	:	UN 3077
IATA	:	UN 3077

**14.2 UN proper shipping name**

ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
IATA	:	Environmentally hazardous substance, solid, n.o.s. (Mometasone)

**14.3 Transport hazard class(es)**

	Class	Subsidiary risks
ADN	:	9
ADR	:	9
RID	:	9
IMDG	:	9
IATA	:	9

## Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

---

**14.4 Packing group****ADN**

Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9

**ADR**

Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9
Tunnel restriction code	:	(-)

**RID**

Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9

**IMDG**

Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F

**IATA (Cargo)**

Packing instruction (cargo aircraft)	:	956
Packing instruction (LQ)	:	Y956
Packing group	:	III
Labels	:	Miscellaneous

**IATA (Passenger)**

Packing instruction (passenger aircraft)	:	956
Packing instruction (LQ)	:	Y956
Packing group	:	III
Labels	:	Miscellaneous

**14.5 Environmental hazards****ADN**

Environmentally hazardous	:	yes
---------------------------	---	-----

**ADR**

Environmentally hazardous	:	yes
---------------------------	---	-----

**RID**

Environmentally hazardous	:	yes
---------------------------	---	-----

**IMDG**

Marine pollutant	:	yes
------------------	---	-----

**IATA (Passenger)**

Environmentally hazardous	:	yes
---------------------------	---	-----

**IATA (Cargo)**

Environmentally hazardous	:	yes
---------------------------	---	-----



## Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

---

**14.6 Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**14.7 Transport in bulk according to Annex II of Marpol and the IBC Code**

Remarks : Not applicable for product as supplied.

---

**SECTION 15: Regulatory information****15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**15.2 Chemical safety assessment**

A Chemical Safety Assessment has not been carried out.

---

**SECTION 16: Other information**

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of H-Statements**

H360Df : May damage the unborn child. Suspected of damaging fertility.

H373 : May cause damage to organs through prolonged or repeated exposure if inhaled.

H410 : Very toxic to aquatic life with long lasting effects.

**Full text of other abbreviations**

Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air

## Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	437335-00019	Date of first issue: 28.01.2016

Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

Repr. 1B	H360Df
STOT RE 2	H373
Aquatic Chronic 1	H410

**Classification procedure:**

Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN